IN2015DN03984A - - Google Patents

Info

Publication number
IN2015DN03984A
IN2015DN03984A IN3984DEN2015A IN2015DN03984A IN 2015DN03984 A IN2015DN03984 A IN 2015DN03984A IN 3984DEN2015 A IN3984DEN2015 A IN 3984DEN2015A IN 2015DN03984 A IN2015DN03984 A IN 2015DN03984A
Authority
IN
India
Prior art keywords
active ingredient
controlled release
pharmaceutical compositions
dosage form
subject invention
Prior art date
Application number
Other languages
English (en)
Inventor
Varinder Ahuja
Rajan Verma
Umesh Vinayakrao Barabde
Arne Hagsten
Kristin Wannerberger
Rambabu Boorugu
Amol Vilasrao Somwanshi
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Priority to IN3984DEN2015 priority Critical patent/IN2015DN03984A/en
Publication of IN2015DN03984A publication Critical patent/IN2015DN03984A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN3984DEN2015 2012-11-21 2013-11-21 IN2015DN03984A (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN3984DEN2015 IN2015DN03984A (fr) 2012-11-21 2013-11-21

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3575DE2012 2012-11-21
IN3947DE2012 2012-12-20
IN3984DEN2015 IN2015DN03984A (fr) 2012-11-21 2013-11-21
PCT/EP2013/074373 WO2014079922A1 (fr) 2012-11-21 2013-11-21 Composition pour libération immédiate et prolongée

Publications (1)

Publication Number Publication Date
IN2015DN03984A true IN2015DN03984A (fr) 2015-10-02

Family

ID=49619947

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3984DEN2015 IN2015DN03984A (fr) 2012-11-21 2013-11-21

Country Status (18)

Country Link
EP (1) EP2922525A1 (fr)
JP (1) JP2016500088A (fr)
KR (1) KR20150085826A (fr)
CN (1) CN104797240A (fr)
AR (1) AR093585A1 (fr)
AU (1) AU2013349682A1 (fr)
BR (1) BR112015011430A2 (fr)
CA (1) CA2891365A1 (fr)
EA (1) EA201590805A1 (fr)
HK (1) HK1213779A1 (fr)
IL (1) IL238648A0 (fr)
IN (1) IN2015DN03984A (fr)
MX (1) MX2015006399A (fr)
PH (1) PH12015501096A1 (fr)
SG (2) SG11201503913TA (fr)
TW (1) TW201422254A (fr)
WO (1) WO2014079922A1 (fr)
ZA (1) ZA201503603B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
ES2923438T3 (es) 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico
CA2978593A1 (fr) 2015-01-12 2016-07-21 Nano Pharmaceutical Laboratories Llc Microbilles multicouches a liberation prolongee et leur procedes de fabrication
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
JP2018526441A (ja) * 2015-09-01 2018-09-13 ウェルズリー ファーマスーティカルズ、エルエルシー 延長、遅延および即時放出製剤、ならびにその製造および使用方法
EP3355864A4 (fr) * 2015-09-30 2019-05-22 Wellesley Pharmaceuticals, LLC Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci
WO2017058436A1 (fr) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
EP3389661A4 (fr) * 2015-12-18 2019-12-18 Wellesley Pharmaceuticals, LLC Composition pour réduire la fréquence de la miction, son procédé de fabrication et d'utilisation
CN109069439A (zh) 2016-04-21 2018-12-21 瓦尔库里亚公司 用于预处理癌症的组合物和方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
RU2751193C2 (ru) * 2017-01-11 2021-07-12 Ферринг Б.В. Быстро распадающаяся фармацевтическая композиция
KR20190021180A (ko) * 2017-08-22 2019-03-05 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4052997A (en) 1996-07-19 1998-02-10 Clarke-Garegg, Margaret A. Levan derivatives, their preparation, composition and applications including medical and food applications
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1064938A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à libération contrôlée avec au moins une impulsion temporelle
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
WO2003094886A2 (fr) * 2002-05-07 2003-11-20 Ferring Bv Preparations pharmaceutiques
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科（北京）研究院有限公司 一种口腔速溶制剂及其生产方法
EP1629834A1 (fr) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Composition pharmaceutique de tolterodine avec liberation soutenue
WO2007029087A2 (fr) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Preparations multi-unites a liberation controlee
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
WO2010053337A2 (fr) * 2008-11-10 2010-05-14 (주)아모레퍼시픽 Particule a liberation lente et procede de production associe
US9078830B2 (en) * 2009-07-31 2015-07-14 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
NZ619857A (en) * 2010-03-29 2015-05-29 Ferring Bv A fast dissolving pharmaceutical composition
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
MX356601B (es) * 2010-03-30 2018-05-29 Productos Maver S A De C V Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada.
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
HK1213779A1 (zh) 2016-07-15
SG10201703388TA (en) 2017-05-30
PH12015501096A1 (en) 2015-07-27
TW201422254A (zh) 2014-06-16
SG11201503913TA (en) 2015-06-29
AU2013349682A1 (en) 2015-06-04
MX2015006399A (es) 2015-07-21
WO2014079922A1 (fr) 2014-05-30
KR20150085826A (ko) 2015-07-24
EA201590805A1 (ru) 2015-11-30
CA2891365A1 (fr) 2014-05-30
AR093585A1 (es) 2015-06-10
JP2016500088A (ja) 2016-01-07
CN104797240A (zh) 2015-07-22
EP2922525A1 (fr) 2015-09-30
BR112015011430A2 (pt) 2017-07-11
ZA201503603B (en) 2016-01-27
IL238648A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
PH12015501096A1 (en) Composition for immediate and extended release
HK1219432A1 (zh) 以嘧啶化合物爲有效成分的醫藥組合物
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
IL238713A0 (en) Self-regulating active pharmaceutical ingredient release
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EP3082817A4 (fr) Compositions pour administration de médicaments
EP2849770A4 (fr) Compositions pharmaceutiques pour l'administration de médicaments pratiquement insolubles dans l'eau
HK1223583A1 (zh) 透皮釋放活性物質的系統
HK1218884A1 (zh) 用於在口腔中釋放至少種活性藥物成分的固體藥物劑型
IL232973B (en) Pharmaceutical preparations containing micelles containing a chelator complex for controlled drug release and uses thereof
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
HK1211021A1 (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions 2--6--9--9h-
ZA201504967B (en) Transdermal dosage form for low-melting point active agent
MX2016001422A (es) Composicion farmaceutica de fingolimod.
IL240666A0 (en) Pharmaceutical preparations for oral administration and their uses
HK1208188A1 (en) Formulations for the delivery of active ingredients
IL236466A0 (en) Pharmaceutical composition for the release of active components
ZA201505084B (en) Monolithic dosage form for the modified release of an active ingredient combination
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
LT2953617T (lt) Farmacinės kompozicijos, apimančios mažų dozių vaistus
HUE049663T2 (hu) Gyógyszerbejuttató rendszer egy vagy több aktív összetevõhöz
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.
MX2015013279A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
IN2013CH02437A (fr)
GB201300437D0 (en) Injectable Active Ingredient Release Compositions and Methods for Their Production and Use